| Species |
Human |
| Protein Construction |
IL-27 [Arg21-Lys229 (IL-27B) & Phe29-Pro243 (IL-27A)]
Accession # Q14213 (IL-27B) & Q8NEV9 (IL-27A) |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by Bis-Tris PAGE |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized Human IL27 RA, hFc Tag at 5μg/ml (100μl/well) on the plate can bind IL-27, His, Human. Test result was comparable to standard batch. |
| Expression System |
CHO |
| Theoretical Molecular Weight |
50.6 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 54-64 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS, 200mM L-arginine (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Interleukin (IL)-27, a member of the IL-6/IL-12 family, has an important role in modulating inflammation in partnership with innate and adaptive immune cells. |
| Synonyms |
Interleukin-27; p28; IL30; IL-27; IL-27A; IL27; p28; |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
